Aegle Therapeutics

Shelley Hartman, CEO
Miami, FL
Aegle Therapeutics is developing a first-in-class therapy using extracellular vesicles, including exosomes, secreted by allogeneic bone marrow derived mesenchymal stem cells to treat severe dermatological conditions including dystrophic epidermolysis bullosa, a rare pediatric blistering disease.

By using this website you agree to accept our Privacy Policy and Terms & Conditions